Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Adhera Therapeutics, Inc. | atrx-20191231xexx322.htm |
| EX-32.1 - EXHIBIT 32.1 - Adhera Therapeutics, Inc. | atrx-20191231xexx321.htm |
| EX-31.2 - EXHIBIT 31.2 - Adhera Therapeutics, Inc. | atrx-20191231xexx312.htm |
| EX-31.1 - EXHIBIT 31.1 - Adhera Therapeutics, Inc. | atrx-20191231xexx311.htm |
| EX-21.1 - EXHIBIT 21.1 - Adhera Therapeutics, Inc. | atrx-20191231xex211.htm |
| EX-4.10 - EXHIBIT 4.10 - Adhera Therapeutics, Inc. | atrx-20191231xexx410.htm |
| 10-K - 10-K - Adhera Therapeutics, Inc. | atrx-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-231219), on Form S-8 (File No. 333-200836), and on Form S-8 (File No. 33-222416) of Adhera Therapeutics, Inc. of our report dated April 14, 2020, relating to the consolidated financial statements of Adhera Therapeutics, Inc. (which expresses an unqualified opinion and includes an explanatory paragraph relating to the Company’s ability to continue as a going concern), appearing in this current report on Form 10-K for the years ended December 31, 2019 and 2018.
/s/ SQUAR MILNER LLP
Los Angeles, California
April 14, 2020